# Safety and Pharmacokinetics of ODM-209

> **NCT03878823** · PHASE1,PHASE2 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 38 (actual)

## Conditions studied

- Prostate Cancer Metastatic
- Advanced Breast Cancer
- Castration-resistant Prostate Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** ODM-209

## Key facts

- **NCT ID:** NCT03878823
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-17
- **Primary completion:** 2024-01-09
- **Final completion:** 2024-01-09
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878823, "Safety and Pharmacokinetics of ODM-209". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03878823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*